Aya Mohamed, Medical Oncologist, Associate Lecturer of Medical Oncology, Member of ASCO, shared a post on X:
“Emerging data suggest that conventional HER2 IHC scoring, originally optimized for Trastuzumab, may be insufficient for predicting response to ADCs such as Trastuzumab deruxtecan.
In this pilot analysis, quantitative HER2 assays (HS-HER2, RPPA, HER2DX) demonstrated superior predictive performance for treatment efficacy compared with standard IHC.
Insight: As ADCs reshape HER2-targeted therapy, more sensitive quantitative HER2 assessment and potentially payload-related biomarkers-may better refine patient selection in precision oncology.”
Title: Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer
Authors: Paolo Tarantino, Se-Eun Kim, Melissa E. Hughes, Ross J. Kusmick, Kalie Smith, Fara Brasó-Maristany, Nay Nwe Nyein Chan, Laia Paré Brunet, Laura Alder, Diana Garcia-Cortes, Jorge Gomez Tejeda Zanudo, Alyssa M. Pereslete, Laura Noteware, Heather Moore, Amanda E. D. Van Swearingen, Tianyu Li, Hersh Gupta, Olivia D’Amico, Alba Martini, Stefania Morganti, Jennifer Spindel, Charmaine Cook, Christine McLaughlin, Kathrin Dvir, Ana C. Garrido-Castro, Sarah Sammons, Janet Files, Kerry Sendrick, Simone Buck, Deborah Dillon, Rinath Jeselsohn, Yvonne Y. Li, Andrew D. Cherniack, Patricia LoRusso, Maryam Lustberg, Rosario Vega-León, Francisco Pardo, Justin Davis, Claudius Mueller, Brian Corgiat, Giuseppe Curigliano, Carey K. Anders, Emanuel F. Petricoin, David L. Rimm, Aleix Prat, Nabihah Tayob, Nancy U. Lin, Sara M. Tolaney
Read the Full Article.
Other articles about Trastuzumab Deruxtecan on OncoDaily.